NEWS FROM. Roswell Park s LEUKEMIA SERVICE
|
|
- Britney Andrews
- 5 years ago
- Views:
Transcription
1 NEWS FROM Roswell Park s LEUKEMIA SERVICE
2 MEET THE LEUKEMIA TEAM PATHOLOGY The Leukemia Service at Roswell Park Cancer Institute () is dedicated to quality patient care, innovative research, and the development of more effective treatments for all hematologic malignancies, including: Acute lymphoblastic leukemia (ALL) THE FIRST PRIORITY Taking diagnosis to a new level Acute myeloid leukemia (AML) Chronic myeloid leukemia (CML) At, a dedicated team of board-certified hematopathologists performs state-of-the-art, integrated diagnostic hematopathology essential to diagnosing and classifying hematolymphoid neoplasms according to the most recent WHO classification. Myelodysplastic syndrome (MDS) Myeloproliferative neoplasms (MPN) (above from left to right) Medical Oncology Meir Wetzler, MD, FACP Pathology is not just looking at cells under the microscope anymore, says George Deeb, MD, Assistant Professor, Director of Hematopathology and Department of Pathology & Laboratory Medicine; Associate Director, Laboratory of Clinical Flow Cytometry. The integrated diagnostic approach is based on comprehensive clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic studies of blood, bone marrow and extramedullary tissue samples. s Leukemia Service takes a team approach to patient care. A leukemia physician oversees a team of fellows, nurse practitioners, physician assistants, pharmacists, social workers, a discharge-planning coordinator, a psychologist and research coordinators. Our nurse practitioner/physician assistant-run clinic in the Chemotherapy/Infusion Center is designed to see patients receiving outpatient chemotherapy or those who have low blood counts and are in need of transfusions. Clinical research conducted by our faculty and staff consistently translates into new therapeutic approaches and advances overall knowledge of the disease. Refer A LEUKEMIA PATIENT We work continually to fortify existing partnerships with the community physicians who entrust their patients to. Hematologic Oncology Elizabeth Griffiths, MD James Thompson, MD Carlos Vigil, MD Eunice Wang, MD Pathology Maurice Barcos, MD, PhD Bora Baysal, MD George Deeb, MD Mihai Merzianu, MD Vishala Neppalli, MD Petr Starostik, MD Paul Wallace, PhD Psychology Megan Pailler, PhD, MA Our hematopathologists work closely with the leukemia clinical team and other ancillary laboratories at to expedite prompt, comprehensive assessments. The ancillary laboratories incorporate the following: bone marrow laboratory immunohistochemistry laboratory with wide arrays of markers available flow and image cytometry laboratory with a spectrum of comprehensive panels of markers to thoroughly characterize hematolymphoid neoplasms immunophenotypically cytogenetic laboratory with karyotypic analysis and large number of FISH probes for many types of genetic abnormalities molecular diagnostic laboratory with a plethora of PCR and sequencing-based analyses. GOING with the FLOW s Flow and Image Cytometry Facility recognized as one of the nation s first and finest analyzes cell samples for clinicians and researchers, leading health centers and many National Institutes of Health clinical studies. This unique facility specializes in leukemias and lymphomas, identifying specific cancer types and subtypes by determining the specific antigen expression of the tumor, using analyses with antibodies and laser-activated flow cytometry. Tracy Roach Senior Patient Access Representative (716) When you suspect or diagnose cancer in your patient, you want the best treatment and care available for that patient. At, we believe in a multidisciplinary team approach. As your patient s primary physician, you remain a key member of this team. We will work closely with you and keep you informed of your patient s treatment and progress. After treatment has been completed and your patient returns to your care, we will continue to provide assistance as needed. With even a suspicion of cancer, your patient can call us and one of our referral professionals will walk him or her through the referral process, answer questions and set up an appointment with the cancer care specialist best suited to the case. Patients may be referred by a physician or may directly seek a consultation and treatment. The Patient Referral Office is open Monday through Friday, 8 am - pm. Call ROSWELL ( ) to seek a consultation or second opinion, or to refer a patient. This integrated diagnostic approach allows us to characterize the tumor s fingerprint, says Dr. Deeb, and provides the most accurate classification that is critical for planning treatment, predicting therapy response and survival, and detecting residual disease or early relapse in leukemia patients. Accurate diagnosis is critical for appropriate treatment. 10% of patients receive a different diagnosis after coming to, as a result of the specialized expertise of the Pathology team at.
3 changed significantly in recent years, there is a dire need for novel approaches," says Meir Wetzler, MD, FACP, Chief, Leukemia Service, For healthcare professionals, quality cancer care tends to be defined by clinical outcomes particularly those that impact patient mortality, morbidity and cost of care and rooted in evidence-based medicine and best practices. Department of Medicine. Leukemia cells from individual patients have been Acute Myeloid Leukemia Acute Myeloid Leukemia (AML) Cases Diagnosed in shown to be biologically diverse. Targeted or genetic abnormality in select leukemia cells may improve outcomes for some leukemia patients without the severe side effects of chemotherapy. For this reason, each leukemia patient undergoes appropriate diagnostic tests to determine whether a targeted therapy is available for their disease subtype. Eligible patients can then access the latest and most recent treatment advances through clinical Blood Marrow Transplant Cases Diagnosed, % AND PROGRAM research studies at. About 0% of leukemia %.% 9.% 0%.9% % Percentage biological agents which block a specific molecular OUR novel targeted approaches for leukemia treatment "Because chemotherapy for leukemia has not 0% 27.% 26.9% 2% 22.9% 2.7% 20.8% 22% 19.% 20% patients at are enrolled in a clinical trial. Trials include tyrosine kinase inhibitors for 1% chronic myeloid leukemia and novel agents for 10% FLT-mutated acute myeloid leukemia and A CENTER OF EXCELLENCE myelofibrosis with and without JAK2 mutations. % 0% 1 2 Year Post-Diagnosis National Cancer Data Base The Blood and Marrow Transplant (BMT) Program at A significant number of patients will receive standard induction treatment for their leukemia because they are not candidates for research performs approximately 100 to 120 blood and Chronic Myeloid Leukemia CasesMyeloid Diagnosed in Chronic Leukemia (CML) marrow transplants each year, treating patients with Cases Diagnosed, hematologic disorders including acute and chronic studies, or for other reasons. Treatment is conducted in a state-of-the art inpatient unit at. The entire unit and its private patient rooms are leukemias, aplastic anemia, Hodgkin and non-hodgkin 90 High Efficiency Particulate-Free Air (HEPA)-filtered. A dedicated team of lymphoma, multiple myeloma, myelodysplastic 80 syndrome, and selected solid tumors % nurses attends to the patients needs. 7% 68.% 61.% In addition, s Leukemia team works closely with the Blood eligibility for transplant. comfort. The entire BMT unit and its 1 private patient rooms are HEPA-filtered. This maintains the highest protection against airborne pathogens. The nursing Prior research at has indicated that low vitamin D staff is specially trained in the management and care levels are associated with poorer outcomes for acute myeloid leukemia. We are currently assessing the effect of vitamin D supplementation in this patient population. of immunocompromised BMT patients, who have special needs. 7.9% % Percentage and Marrow Transplant team to assess each patient s need and 61.% 60 s BMT unit was designed for patient safety and.2% 9.2% 0.7% Year Post-Diagnosis National Cancer Data Base ROLE OF VITAMIN D The statistical data presented here has been benchmarked against data collected by SEER, NCDB, Press Ganey and NCCN.
4 From bench to bedside translational research at Translational research, which aims to bring new discoveries to the clinic to help patients as quickly as possible, is the hallmark of Support every the investigative efforts of s Leukemia Team. It begins in the laboratory, where researchers define an aberration within a cell and strive to correct it, an endeavor that has led to the development of many medications we use today. researchers are investigating a number of pathways in leukemia, and this work has already led to several clinical studies for patients. Currently we are investigating: step way of the The role of signal transducer and activator of transcription in INTEGRATING PSYCHOSOCIAL SUPPORT INTO EVERY PATIENT S CARE leukemogenesis; cellular and humoral immune response to leukemicassociated antigens; and cytogenetics in AML and ALL The role of angiogenesis and hypoxia in promoting acute leukemia; and the genetic analyses of leukemias. The etiology of MDS and unexplained anemia (UA) of aging; the role of mitochondrial DNA (mtdna) mutations in immunosenescence; and the role of mtdna mutations in the development of MDS and UA. Epigenetic changes in leukemia and myelodysplastic syndromes, and novel therapeutics for elderly patients with Acute Myeloid Leukemia Novel therapies for hematologic malignancies; oxidative stress mechanisms in hematologic malignancies; and erythropoiesis and hypoxia. Adjusting to diagnosis and coping with treatment is difficult for most cancer patients, but those with acute leukemia often face unique challenges. Certain factors about leukemia, such as the very short time between diagnosis and treatment, extended hospitalization and duration of care, put a significant strain on patients and their families, says Megan Pailler, PhD, Medical Psychologist. offers extensive psychosocial services for leukemia patients, including support at the time of a new diagnosis, psychological assessment, psychotherapy for patients and their families, and a caregiver orientation program for family members of all newly diagnosed leukemia patients. As a comprehensive cancer center, this is what sets us apart, says Dr. Pailler. We treat the whole person, not just the cancer. Psychosocial services are fully integrated into the treatment and care patients receive here. In addition, the Social Work Department offers leukemia patients a number of services to support them and their families throughout treatment. Patients don t have the time to prepare or plan for a long hospital stay. Our Social Services, while beneficial to many cancer patients, are often essential for those with leukemia. SOCIAL WORK AND PSYCHOLOGY SERVICES Educational and orientation programs to help patients understand their disease and its treatment Assistance in navigating the Family Medical Leave Act (FMLA), sick leave and disability Help with lodging, transportation or language/interpreter needs Connections to financial assistance programs and other community resources 6 Results from our clinical trials have raised new questions, leading to new bench research, called retro-translational research. Hematologic Procurement Facility This facility allows to collect and bank tissue samples from all patients with hematologic malignancies. We study these samples to better understand characteristics of individual patients disease, and this leads to new findings and the development of better clinical studies for leukemia patients. Assistance with advance care planning, palliative care and/or hospice as needed 7
5 Setting the National Standards Roswell Park Cancer Institute plays a key role in developing the National Comprehensive Cancer Network (NCCN) guidelines that specify the best ways of preventing, detecting and treating specific types of cancer. The NCCN guidelines, based on scientific data, are the most widely used standards for cancer care. These physicians are members of NCCN guideline panels. Meir Wetzler, MD, FACP, Chief, Leukemia Section, Assistant Research Professor, Department of Immunology; serves on the Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia Panels. James Thompson, MD, Assistant Professor of Oncology, Department of Medicine; Assistant Member, Department of Immunology; serves on the Myelodysplatic Syndromes Panel. Carlos Vigil, MD, Assistant Professor, Leukemia Service, serves on the Cancerand Chemotherapy- Induced Anemia Panel. Eunice Wang, MD, Assistant Professor, Assistant Member, Tumor Immunology Program; serves on the Acute Myeloid Leukemia Panel. = NCCN Cancer Centers Visit for more information (1/6/12)
NEWS FROM. Roswell Park s LEUKEMIA SERVICE
NEWS FROM Roswell Park s LEUKEMIA SERVICE MEET THE LEUKEMIA TEAM The Leukemia Service at Roswell Park Cancer Institute (RPCI) is dedicated to quality patient care, innovative research, and the development
More informationNEWS FROM. Roswell Park s LYMPHOMA AND MYELOMA SERVICE
NEWS FROM Roswell Park s LYMPHOMA AND MYELOMA SERVICE MEET THE LYMPHOMA & MYELOMA TEAM The Lymphoma and Myeloma Service at Roswell Park Cancer Institute (RPCI) is dedicated to providing outstanding clinical
More informationBlood & Marrow Transplant Leukemia Immunotherapy
Blood & Marrow Transplant Leukemia Immunotherapy Our Physicians Our specially trained physicians provide leadership for the Northside Hospital Blood and Marrow Transplant, Leukemia and Immunotherapy Programs,
More informationNEWS FROM. Roswell Park s BLOOD AND MARROW TRANSPLANT PROGRAM
NEWS FROM Roswell Park s BLOOD AND MARROW TRANSPLANT PROGRAM THE BLOOD AND MARROW TRANSPLANT TEAM Philip McCarthy, MD Medical Director, BMT Program Hong Liu, MD, PhD Attending Physician Our multidisciplinary
More informationBlood & Marrow Transplantation Center
Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs about
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationHematologic Malignancies 2013 Retrospective Study at Truman Medical Center
Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Kristen Strasser, MD & Abdulraheem Qasem, MD Introduction: Hematologic Malignancies includes malignant diseases of the bone marrow
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationThe Blood & Marrow Transplantation Center
The Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs
More informationCleveland Clinic Laboratories Hematology Diagnostic Services. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent
More informationCareers in Pediatric Hematology/Oncology
Careers in Pediatric Hematology/Oncology Prepared by The American Society of Pediatric Hematology/Oncology ASPHO 8735 W. Higgins Rd., Suite 300, Chicago, IL 60631 847.375.4716 aspho.org ABOUT ASPHO The
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationImproving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: A Workshop
Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: A Workshop Diagnostic Management Teams (DMT) The Vanderbilt University Medical School
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More information2019 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT: with Proceedings from International Medical Meetings
Continuing Medical and Interprofessional Education FRIDAY, FEBRUARY 1, 2019 7:30 AM - 4:30 PM The Rittenhouse Hotel 210 W Rittenhouse Square Philadelphia, PA 19103 Penn Medicine s Abramson Cancer Center
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More information2018 UPDATE IN HEMATOLOGIC MALIGNANCIES with Proceedings from International Medical Meetings
FRIDAY, JANUARY 26, 2018 7:30 AM 4:30 PM Hilton Philadelphia City Avenue 4200 City Avenue Philadelphia, PA 19131 Penn Medicine s Abramson Cancer Center and the Leukemia & Lymphoma Society PRESENT 2018
More informationElliot Senior Specialty Services. in Greater Manchester. 138 Webster Street Manchester NH
Elliot Senior Specialty Services in Greater Manchester 138 Webster Street Manchester NH 03104 603-663-7000 Dedicated to helping seniors achieve their maximum quality of life ELLIOT SENIOR SPECIALTY SERVICES
More informationLEUKEMIAS 2017 ACUTE & CHRONIC ENCORE AT WYNN LAS VEGAS LAS VEGAS, NEVADA OCTOBER 6 7, 2017
Jointly provided by Mayo School of Continuous Professional Development and Mayo Continuing Nursing Education ACUTE & CHRONIC LEUKEMIAS 2017 REGISTER NOW! $75 DISCOUNT For Early Registration Expires 9/6/2017
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationHematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationWith Proceedings from International Medical Meetings
Penn Medicine s Abramson Cancer Center and the Leukemia & Lymphoma Society PRESENT UPDATE IN HEMATOLOGIC CANCERS With Proceedings from International Medical Meetings REGISTER ONLINE AT PENNCANCER.ORG/CME/BLOOD
More informationJANUARY 22, :00 AM 4:30 PM
FRIDAY, JANUARY 22, 2016 8:00 AM 4:30 PM Hilton Hotel 4200 City Avenue Philadelphia, PA 19131 Penn Medicine s Abramson Cancer Center and the Leukemia & Lymphoma Society PRESENT UPDATE IN HEMATOLOGIC CANCERS
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Hematology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology Faculty representative: Neil Weiner, MD Resident representative: Guiherme Rabinowits, MD Revision date: February 28, 2006 Goals
More informationCheck out ASH s VIDEO LIBRARY for Useful Teaching Tools
Check out ASH s VIDEO IBRARY for Useful Teaching Tools ASH offers a number of FREE videos that are perfect for students. ASH s video library includes films on a variety of topics including: Cancer Cells
More informationa d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s Summer 2017 For more information, visit www.dfbwcc.org/bmt. o u r expertise
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More informationCancer Care at HackensackUMC Mountainside. Unsurpassed Quality, Safety, Comfort and Convenience
Cancer Care at HackensackUMC Mountainside Unsurpassed Quality, Safety, Comfort and Convenience A Nationally Recognized Standard of Care A Supportive, Community Setting In the years that HackensackUMC Mountainside
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationVA Hematology/Oncology Elective
VA Hematology/Oncology Elective The Medical Oncology and Hematology section at the Syracuse VA Medical Center is responsible for providing specialized care to our veterans with cancer and blood disorders.
More informationBreast Cancer Services
Breast Cancer Services World Class, Comprehensive Care University of Colorado Hospital has the only multidisciplinary breast care clinics in the region. CU Cancer Center is the only National Cancer Institute-designated
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationHighlights from the 2017 Annual Meeting of the American Society of Hematology
Latest NEWS IN BLOOD CANCER RESEARCH Highlights from the 2017 Annual Meeting of the American Society of Hematology CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series
More informationCurriculum: Goals and Objectives Department of Medicine Harbor-UCLA Medical Center
MEDICAL ONCOLOGY AND HEMATOLOGY (R2, R3) A. The PURPOSE of this rotation is to afford medical residents a broad clinical and training experience in the clinical diagnosis and management of common adult
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationNUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow
Quality ID #67 (NQF 0377): Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow National Quality Strategy Domain: Effective Clinical Care
More informationDEPARTMENT OF MEDICAL ONCOLOGY
DEPARTMENT OF MEDICAL ONCOLOGY DEPARTMENT OF MEDICAL ONCOLOGY About Narayana Health City One of the leading private healthcare service providers in India, operating a chain of multispecialty, tertiary
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationIn this program you will learn
1 In this program you will learn How to gather information to help you make treatment decisions Questions to ask about the benefits and risks of any treatment How new blood cancer treatments are developed
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationStudying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
More information28 OI November December A Medical Home for Adolescents and Young Adults with Cancer
28 OI November December 2013 www.accc-cancer.org A Medical Home for Adolescents and Young Adults with Cancer By Douglas S. Hawkins, MD Our team consists of more than 30 doctors specializing in cancers
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationNaef K. Basile Cancer Institute (NKBCI)
Naef K. Basile Cancer Institute (NKBCI) www.aubmc.org Copyright 2016 American University of Beirut. All rights reserved. 1 In your fight against cancer, our dedication will keep you strong. 2 The Naef
More informationDOWNLOAD OR READ : TREATMENT OF ACUTE LEUKEMIAS NEW DIRECTIONS FOR CLINICAL RESEARCH REPRINT PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF ACUTE LEUKEMIAS NEW DIRECTIONS FOR CLINICAL RESEARCH REPRINT PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of acute leukemias new directions for clinical research reprint
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationUnderstanding Treatment-Free Remission and How It Impacts You
Understanding Treatment-Free Remission and How It Impacts You Written by Michael J. Mauro, M.D. Leader, Myeloproliferative Disorders Program Memorial Sloan Kettering Cancer Center Professor of Medicine,
More informationCleveland Clinic Laboratories. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Trust in us for everything you need in a reference lab. 2 Cleveland Clinic Laboratories At Cleveland Clinic Laboratories, we recognize the results we turn out are pivotal
More informationAnnual Report Division of Hematology Department of Medicine, Jewish General Hospital April 1, December 31, 2011
Annual Report Division of Hematology Department of Medicine, Jewish General Hospital April 1, 2011 - December 31, 2011 I HIGHLIGHTS A) Segal Cancer Center After more than five years of operation in the
More informationEosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation
Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation American Society for Clinical Pathology 2014 Annual Meeting Presented by: Matthew T. Howard, MD Assistant
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationPractical Diagnosis of Hematologic Disorders. Vol 2 Malignant Disorders
5 th ed Practical Diagnosis of Hematologic Disorders Vol 2 Malignant Disorders Vol2_FrontMatter_v03_0804 final.indd i 8/6/2009 10:00:11 PM Authors Carl R Kjeldsberg, MD Professor of Pathology, University
More informationOverview...3. Cancer Program.4. Breast Cancer with 5-year Survival Analysis...6. Systemic Therapy.7. Stage of Breast Cancer Diagnosed in
2011 Annual Report Table Of Contents Overview...3 Cancer Program.4 Breast Cancer with 5-year Survival Analysis...6 Systemic.7 Stage of Breast Cancer Diagnosed in 2008..8 Radiation and Systemic Only...9
More informationHEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain
More informationA GUIDE TO STARTING TREATMENT
A GUIDE TO STARTING TREATMENT Please see accompanying and Medication Guide. full Prescribing IDHIFA (enasidenib) is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an
More informationPeripheral Blood Smear: Diagnostic Clues and Algorithms
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information2402: Pre-TED Disease Classification
2402: Pre-TED Disease Classification The Pre-TED Form is now required for all transplants, including subsequent transplants on * the comprehensive report form track. All transplant centers participating
More informationCase Report. Introduction. Mastocytosis associated with CML Hematopathology - March K. David Li 1,*, Xinjie Xu 1, and Anna P.
Mastocytosis associated with CML Hematopathology - March 2016 Case Report Systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) involving chronic myelogenous
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationCME. Controversies in Hematologic Malignancies. Annual Oncology Symposium: Friday, May 20, 2016
Annual Oncology Symposium: Controversies in Hematologic Malignancies CME continuing medical education Friday, May 20, 2016 Glaser Auditorium Swedish First Hill Seattle, Washington Needs Statement Research
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationCleveland Clinic Laboratories. Anatomic Pathology
Cleveland Clinic Laboratories Anatomic Pathology OUR MISSION Cleveland Clinic Laboratories contributes to excellent patient care by providing high-quality, comprehensive laboratory testing and patient-focused
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationTechnical Bulletin No. 100
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.
More informationPGY-2 ONCOLOGY RESIDENCY ROTATION DESCRIPTION
PGY-2 ONCOLOGY RESIDENCY ROTATION DESCRIPTION ROTATION TITLE Outpatient Adult Oncology PURPOSE The outpatient oncology service will provide the PGY-2 resident with the opportunity to further develop and
More informationAcute Lymphoblastic Leukaemia Guidelines
Acute Lymphoblastic Leukaemia Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Adele Fielding, Royal Free London NHS Trust Date of issue: 12.03.2015 Version number:
More informationPalliative Care for Older Adults in the United States
Palliative Care for Older Adults in the United States Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Icahn School
More informationCITY OF HOPE PROSTATE CANCER OUTCOME SUMMARY
CITY OF HOPE PROSTATE CANCER OUTCOME SUMMARY City of Hope s median survival surpasses SEER LA in Stages I IV Prostate Cancer* Surveillance, Epidemiology, and End Results Program *Based on SEER data from
More informationCancer Center Services Guide
Cancer Center Services Guide A Place of Hope and Healing Since 1999, the Robert and Carol Weissman Cancer Center at Martin Health has combined medical expertise with advanced technology for the most promising
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationCURRICULUM VITAE. Dr.Eman Kandeel
CURRICULUM VITAE Dr.Eman Kandeel Name : Eman Zaghloul Kandeel Address : ALHaram St. Al Giza, Egypt. Telephone: 002 01001543088 002 33302147 Nationality: Egyptian Date of birth: 19/12/1977 Marital status:
More informationIn this monthly feature, NewsLine
In this monthly feature, NewsLine shines the light on a hospice organization which has expanded services or has partnered with other community organizations to reach patients earlier in the illness trajectory
More informationACUTE LYMPHOBLASTIC LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T
More information